Citalopram

Introduction Overview

Generic Name

citalopram

Brand Name

Celexa

Dosage Form

oral tablet (10 mg; 20 mg; 40 mg)

Drug Class

Selective serotonin reuptake inhibitors (SSRIs)

Pharmacokinetics

Absorption:
Citalopram demonstrates efficient gastrointestinal absorption following oral administration, with bioavailability approximating 80%. Peak plasma concentrations are typically achieved within 4 hours post-dose. Food intake does not significantly affect citalopram absorption, enabling flexibility in dosing with or without meals. The absorption process is consistent across varied patient populations, although delayed gastric emptying conditions may marginally influence the rate but not the extent of absorption.

Distribution:
Citalopram exhibits a volume of distribution of approximately 12–22 L/kg, indicating extensive tissue penetration. It is moderately bound to plasma proteins (around 80%), predominantly albumin. The drug crosses the blood-brain barrier efficiently to exert central nervous system effects and can also be detected in cerebrospinal fluid. Citalopram's distribution features neuronal uptake in serotonergic pathways, critical for its antidepressant effect.

Metabolism:
Metabolized primarily by hepatic cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19, citalopram undergoes N-demethylation to produce desmethylcitalopram, an active metabolite with a lesser pharmacological effect. Further biotransformation involves demethylation and oxidation steps. Metabolic rate can vary based on genetic polymorphisms affecting CYP2C19 and CYP3A4 activity, necessitating dose adjustments in poor metabolizers or patients on concomitant CYP-modulating agents. Hepatic impairment may reduce clearance and prolong half-life.

Elimination:
Citalopram and its metabolites are primarily eliminated via renal excretion, with approximately 12–23% of the unchanged drug excreted in urine. The elimination half-life averages 35 hours but may extend up to 50 hours in elderly or hepatic-impaired patients. Steady-state concentrations are reached within one week of daily dosing. Renal impairment has minimal impact on pharmacokinetics, but dosage adjustment may be prudent with severe renal dysfunction. The prolonged elimination half-life supports once-daily dosing regimens.

Dosage Forms

Available Dosage Forms:
Celexa is available as oral tablets in strengths of 10 mg, 20 mg, and 40 mg, formulated for once-daily administration. These tablets comprise citalopram hydrobromide as the active ingredient alongside excipients such as copolyvidone, corn starch, crosscarmellose sodium, glycerin, lactose monohydrate, magnesium stearate, hypromellose, microcrystalline cellulose, polyethylene glycol, titanium dioxide, and iron dioxide for coloring.

Dosages for Adults and Adolescents:
The typical initial dose for adults with major depressive disorder is 20 mg once daily, which may be titrated to a maintenance dosage of 20-40 mg per day based on clinical response and tolerability. Dose escalation beyond 40 mg daily is not recommended due to lack of additional efficacy and increased risk of adverse effects, including QT prolongation. In acute depressive episodes, treatment duration often extends several months to achieve sustained remission.

Specific Patient Populations:
For elderly patients (over 60 years), the recommended maximum dose is 20 mg daily to reduce the risk of QT prolongation and adverse effects. Dose adjustments should be considered in patients with moderate to severe hepatic impairment, and caution is advised in patients with electrolyte disturbances or a history of cardiac arrhythmias. In patients with renal impairment, no formal dose modification is usually necessary but monitoring is recommended. Pediatric use is not broadly approved; any off-label use requires careful consideration of growth and development monitoring.

Clinical guidelines emphasize careful dose titration with regular monitoring for tolerability, adverse effects, and emergence of suicidality.

Mechanism Of Action

Citalopram is a potent and highly selective inhibitor of the serotonin transporter (SERT) in presynaptic neurons, leading to increased availability of serotonin (5-hydroxytryptamine, 5-HT) in the synaptic cleft. This augmentation of serotonergic transmission in the central nervous system is believed to underlie citalopram’s antidepressant effects. Unlike tricyclic antidepressants and monoamine oxidase inhibitors, citalopram exhibits minimal affinity for adrenergic, histaminergic, or cholinergic receptors, contributing to its favorable side effect profile.

On a molecular level, citalopram binds to SERT with high affinity, blocking the reuptake of serotonin into presynaptic nerve terminals, thereby enhancing serotonergic neurotransmission particularly in limbic regions such as the hippocampus and prefrontal cortex, which are implicated in mood regulation. This increased serotonergic signaling mediates neuroplastic changes, including upregulation of postsynaptic 5-HT receptors over time, which correlates with clinical improvement in depressive symptoms.

At the cellular pathway level, chronic administration of citalopram influences downstream intracellular signaling cascades, including cyclic AMP-mediated pathways, modulating gene expression relevant to neuronal survival, neurogenesis, and synaptic remodeling. These neuroadaptive changes contribute to the delayed onset of antidepressant efficacy commonly observed with SSRIs.

Comparatively, citalopram is a racemic mixture while escitalopram, its S-enantiomer, demonstrates greater pharmacological potency and selectivity. Clinical studies indicate that while both exhibit SSRI mechanisms, citalopram’s racemic nature may confer differences in receptor binding and side effect profiles. The clinical implications include effective treatment of major depressive disorder with a relatively low burden of side effects. Extensive research substantiates citalopram's efficacy and safety in a wide range of depressive and anxiety-related disorders.

Pharmacological Actions

Selective inhibition of serotonin reuptake at presynaptic neurons, increasing extracellular serotonin levels.
Enhancement of serotonergic neurotransmission in brain regions implicated in mood and affect regulation.
Modulation of postsynaptic 5-HT receptor density and function following chronic administration.
Minimal interaction with adrenergic, histaminergic, and cholinergic receptors, reducing anticholinergic and sedative side effects.
Promotion of neuroplasticity and synaptic remodeling through intracellular signaling pathways.
Improvement of mood, anxiety, and other neuropsychiatric symptoms associated with serotonin deficiency.
Stabilization of emotional regulation circuits through long-term serotonergic activity enhancement.
Limited impact on norepinephrine and dopamine systems compared to other classes of antidepressants.
Reduction of depressive symptomatology including anhedonia, mood disturbances, and cognitive impairments.
Possible downstream effects on hypothalamic-pituitary-adrenal axis normalization.
Action as a racemic mixture with differential binding affinities of enantiomers influencing pharmacodynamic effects.

Therapeutic Or Clinical Uses

Treatment of major depressive disorder (MDD) in adults.
Management of generalized anxiety disorder (off-label uses based on SSRI pharmacology).
Adjunctive therapy in obsessive-compulsive disorder (in some clinical contexts).
Use in panic disorder management due to serotonergic modulation.
Potential application in post-stroke depression with careful cardiovascular monitoring.
Off-label use in social anxiety disorder and post-traumatic stress disorder.
Treatment of depressive episodes associated with bipolar disorder under specialist supervision.
Alleviation of certain chronic pain syndromes linked to central serotonin pathways.
Symptomatic relief of premenstrual dysphoric disorder symptoms (off-label use).
Potential utility in managing hot flashes in menopausal patients.
Improvement of neurovegetative symptoms including sleep and appetite disturbances related to depression.

Side Or Adverse Effects

Sexual dysfunction including decreased libido, delayed ejaculation, anorgasmia, and erectile dysfunction.
Central nervous system effects such as dizziness, drowsiness, and insomnia.
Gastrointestinal disturbances including nausea, diarrhea, constipation, and dry mouth.
Increased sweating (hyperhidrosis) and thirst.
Feeling anxious, restless, agitated, or experiencing tremor.
Fatigue, weakness, and yawning.
Increased muscle movements or tremors.
Nosebleeds and heavy menstrual bleeding (menorrhagia).
Cold-like symptoms such as nasal congestion, sneezing, and sore throat.
Serious allergic reactions including urticaria, facial swelling, or respiratory difficulty.
Risk of serotonin syndrome when combined with other serotonergic agents.
Potential QT interval prolongation leading to serious cardiac arrhythmias.
Manic episodes or mood destabilization in bipolar disorder patients.
Hyponatremia with symptoms such as headache, confusion, and seizures, especially in the elderly.
Rare but serious nervous system reactions like stiffness, high fever, sweating, and tremors.

Precautions

Do not discontinue citalopram abruptly; taper dose gradually to reduce withdrawal symptoms.
Use cautiously in patients with a history of bipolar disorder to prevent manic episodes.
Monitor cardiac function in patients with pre-existing heart conditions and those over 60 years due to QT prolongation risk.
Avoid concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI therapy to prevent serotonin syndrome.
Assess electrolyte imbalances such as hypokalemia or hypomagnesemia prior to treatment initiation.
Exercise caution in patients with seizure disorders given rare seizure potential.
Monitor for worsening depression or emergence of suicidal ideation, especially in young adults and adolescents.
Consider potential drug interactions with concomitant serotonergic or QT-prolonging agents.
Advise patients against alcohol consumption during treatment due to additive CNS depressant effects.
Recommend pregnancy risk assessment and enrollment in pregnancy exposure registries if applicable.
Evaluate risks versus benefits during breastfeeding; consult healthcare provider.
Monitor for sexual dysfunction and provide management strategies or alternative therapies if needed.
Use caution in patients with narrow-angle glaucoma since SSRIs may increase intraocular pressure.
Regular liver and kidney function monitoring is advisable in patients with organ impairment.
Educate patients about signs of serotonin syndrome and when to seek immediate medical attention.

Warnings

Citalopram can cause serious heart problems, including QT interval prolongation and potentially fatal arrhythmias.
Avoid use in combination with pimozide or other QT-prolonging drugs due to increased cardiac risk.
Do not use if an MAO inhibitor has been taken within the past 14 days; risk of fatal interaction.
Increased risk of suicidal thoughts and behaviors in young adults, adolescents, and children when initiating antidepressants.
Serotonin syndrome is a potentially life-threatening condition requiring immediate medical intervention when symptoms appear.
Discontinue therapy carefully under medical supervision to avoid severe withdrawal symptoms such as agitation, sensory disturbances, or confusion.
Potential for manic/hypomanic episodes in patients with bipolar disorder; monitor mood changes vigilantly.
May impair judgment, thinking, or motor skills; use caution when driving or operating machinery.
Pregnancy exposure during the third trimester may harm the fetus; balance treatment benefits against potential risks.
Postpartum hemorrhage risks may increase, particularly with SSRI exposure near delivery.
Citalopram may cause abnormal bleeding; use with caution in patients on anticoagulants or with bleeding disorders.
Use with NSAIDs may increase bleeding risk; careful monitoring is necessary.
Sexual dysfunction may persist and can impact quality of life; discuss openly with patients.
Elderly patients are at increased risk of hyponatremia and related complications.
Monitor for signs of severe allergic reactions or hypersensitivity.

Contraindication

Known hypersensitivity to citalopram, escitalopram, or any of the excipients.
Concomitant use with pimozide due to risk of severe cardiac arrhythmias.
Use within 14 days of discontinuing an MAO inhibitor or within 14 days prior to starting an MAO inhibitor.
History of congenital long QT syndrome or patients with known QT prolongation.
Patients with recent myocardial infarction or unstable heart conditions should avoid citalopram until stabilized.
Concurrent use with methylene blue injection because of serotonin syndrome risk.
Use in patients with seizure disorders requires careful benefit-risk assessment but generally contraindicated if uncontrolled.
Concomitant use with other serotonergic agents without appropriate monitoring due to serotonin syndrome risk.
Known allergic reactions presenting as anaphylaxis or severe cutaneous adverse reactions to SSRIs.
Use in pediatric patients is generally not approved for depression treatment; contraindicated without specialist evaluation.
Patients with history of angle-closure glaucoma without prophylactic treatment.
Severe hepatic impairment due to altered metabolism and elimination.
Patients with electrolyte imbalances who cannot be adequately corrected before treatment.

Drug Interactions

Monoamine oxidase inhibitors (MAOIs): concomitant use can precipitate serotonin syndrome and is contraindicated.
Other serotonergic drugs such as triptans, tramadol, lithium, buspirone, and St. John’s Wort increase serotonin syndrome risk.
Drugs that prolong QT interval (e.g., certain antipsychotics, antiarrhythmics, methadone) can exacerbate cardiac risks.
Cimetidine may increase plasma citalopram levels by inhibiting CYP enzymes.
Warfarin and other anticoagulants may have enhanced bleeding risk when combined with citalopram.
Diuretics can exacerbate electrolyte imbalances increasing risk for QT prolongation.
Opioids including methadone and fentanyl may pose additive risks of sedation and serotonin syndrome.
Fluoroquinolone antibiotics such as gatifloxacin and moxifloxacin may increase QT prolongation risk.
St. John’s Wort reduces citalopram plasma levels while enhancing serotonergic activity, increasing adverse outcomes.
Concomitant NSAIDs or aspirin increase bleeding risk due to platelet function impairment.
Tricyclic antidepressants metabolism may be altered by citalopram, affecting therapeutic and side effect profiles.
Benzodiazepines may have altered pharmacodynamics when combined with citalopram, affecting sedation.
Drugs metabolized by CYP3A4 and CYP2C19 may have altered plasma concentrations due to citalopram's inhibitory effects.
Alcohol potentiates CNS depressant effects and should be avoided.
Linezolid and methylene blue injections are contraindicated due to elevated serotonin syndrome risk.

Preparations Of The Drug

Active ingredient: citalopram hydrobromide.
Inactive ingredients include copolyvidone, corn starch, crosscarmellose sodium.
Excipients such as glycerin, lactose monohydrate, magnesium stearate for tablet formulation.
Tablet coatings composed of hypromellose, microcrystalline cellulose, polyethylene glycol.
Colorants titanium dioxide and iron dioxide to differentiate tablet strengths.
Available exclusively as oral tablets in strengths of 10 mg, 20 mg, and 40 mg.
Packaging designed to protect from moisture and light, maintaining drug stability.
Distributed by Allergan USA Inc, Madison, NJ, USA.
Manufactured under stringent quality control following FDA guidelines for pharmaceutical production.
Supplied with patient medication guides detailing usage, side effects, and precautions.
Tablets formulated for once-daily dosing ensuring steady plasma drug levels.
Inert excipients selected to minimize risk of allergic reactions and enhance tablet disintegration.